Natus Medical Incorporated
If you purchased Natus Medical Incorporated securities and would like to join the action, please click "Join This Action" below.
NTUS STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF NATUS MEDICAL INCORPORATED IS FAIR TO SHAREHOLDERS
April 18, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Natus Medical Incorporated (NASDAQ: NTUS) to an affiliate of ArchiMed for $33.50 in cash per share is fair to Natus Medical shareholders.
The investigation concerns whether Natus Medical and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Natus Medical shareholders; (2) determine whether ArchiMed is underpaying for Natus Medical; and (3) disclose all material information necessary for Natus Medical shareholders to adequately assess and value the merger consideration. On behalf of Natus Medical shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.